Followers | 3183 |
Posts | 208744 |
Boards Moderated | 2 |
Alias Born | 02/04/2004 |
Friday, January 20, 2017 11:29:00 AM
COLL and IPCI both have their own delivery platforms, therefore neither of them were relying on Purdue's oxy patent that expires in 2025.
Purdue's original oxycodone molecule expired in 2013 but Purdue saw the writing on the wall and came up with the reformulated product in 2010 which only addressed the snorting and injection parts of abuse. This allowed them the extended patent expiration timeframes on their reformulated version...the patent "protection" of which expire later in 2017(have to look up the exact date but if memory serves it's definitely b4 August 2017 for protection expiry)
So in a nutshell Collegium already got any potential Purdue lawsuit dirty work out of the way and there's not enough remaining time in Purdue's reformulated patent protection to file a lawsuit against IPCI...especially since COLL already prevailed over Purdue in such a resounding fashion...and IPCI's potential Rexista FDA approval is still approximately 6 months out!
Also of interesting note, Purdue filed their lawsuit against COLL the moment COLL filed their NDA...but Purdue did not file any lawsuit against IPCI the moment IPCI filed their Rexista NDA on November 25th.
As well, COLL's oxy has to be taken with food...whereas IPCI's doesnt. Therefore IPCI will have a tremendous advantage coming to market as the only oxy product that can be taken with or without food!
With all the above said, Purdue isn't going to be launching any lawsuit against IPCI because their reformulated oxy patent protection which IPCI's NDA is relying on expires this August(or sooner)...and it's far more likely that Purdue is 1 of the companies behind the scenes that IPCI's held talks with over the past year.
Just my take on the entire Purdue lawsuit speculation that gets brought up from time to time
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - IPCI • PR Newswire (Canada) • 06/08/2023 05:30:00 PM
- Canadian Investment Regulatory Organization Trade Resumption - IPCI • PR Newswire (Canada) • 06/08/2023 05:28:00 PM
- Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results • PR Newswire (Canada) • 06/06/2023 10:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM